Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of BIOTRONIK dual-chamber pacemakers that combine left bundle branch area pacing LBBAP with Closed Loop Stimulation CLS in patients who have sinus node dysfunction SND and atrioventricular AV conduction disorders. This observational study aims to understand how this combined pacing method works in everyday clinical practice and whether it can help reduce atrial fibrillation detected by the device over 24 months. The goal is to gather real-world evidence to optimize pacemaker programming and improve patient outcomes. Participants receive permanent dual-chamber pacemakers with a ventricular lead placed in the left bundle branch area, activating the CLS rate-responsive algorithm. The study focuses on patients implanted with these devices who have no prior history of atrial fibrillation. The study follows about 150 patients for 24 months after implantation, collecting data on device-detected atrial fibrillation episodes, heart rate patterns, and pacing behavior. This is a prospective observational submodule of the BIOSTREAM.CSP registry without a control group. During the study, researchers monitor device-recorded atrial fibrillation incidence and burden from CLS activation up to 24 months. They also analyze heart rate histograms at one and two years after implantation. Patients are enrolled in the BIOSTREAM.CSP registry and are followed through routine clinical care with data collected on pacing rates and arrhythmia episodes. The study aims to provide insights into the clinical performance of CLS combined with LBBAP to inform decisions on pacemaker programming and reduce atrial arrhythmias.
Actively Recruiting
The registry is designed to evaluate the outcomes, performance, and safety of BIOTRONIK devices used in conduction system pacing CSP through long-term data collected in real-world clinical settings. It includes patients who receive these devices as part of routine care to better understand their use and effects over time. The study is observational and collects data from unselected patients without intervention by the researchers. Participants receive BIOTRONIK devices for conduction system pacing, including the implantation of the Solia CSP S pacing lead for left bundle branch area pacing LBBAP. The study includes patients who are newly implanted, recently implanted but not yet discharged, or transitioning from a related study. The registry tracks device performance and safety over an average of 4 years through annual assessments. During the study, participants will undergo evaluations including the rate of device-related serious adverse events, success of acute implantation, capture type at implantation, long-term maintenance of pacing, and electrical parameters such as pacing threshold, sensing amplitude, and impedance. Participants will use the BIOTRONIK Home Monitoring system with the CardioMessenger device to support follow-up, which requires their willingness and ability to comply with study visits and monitoring over time.
Actively Recruiting
Researchers are studying the use of the serratus posterior superior intercostal plane SPSIP block as a pain relief method for adults having shoulder arthroscopy. This observational study aims to describe how the sensory block spreads in the shoulder area and how much it spares motor function in the upper limb and diaphragm. The SPSIP block targets nerves away from the brachial plexus and phrenic nerve, potentially reducing motor and diaphragmatic effects compared to the standard interscalene block. Participants will receive the SPSIP block before their shoulder arthroscopy surgery. Sensory response will be tested 30 minutes after the block using a cold cotton swab applied over defined areas of the shoulder. Motor function of the shoulder will be measured before and 30 minutes after the block by assessing shoulder abduction and external rotation. Diaphragmatic movement will be evaluated using ultrasound during deep breathing, also before and 30 minutes after the block. Surgery will follow under general anesthesia, without additional intraoperative measurements. During the study, participants will be assessed for sensory sensation differences between the operated and opposite shoulder, motor range of motion, and diaphragmatic excursion. Data on demographics and the local anesthetic used will be recorded. The main outcome is sensory blockade at 30 minutes post-block. Secondary outcomes include motor sparing and diaphragm function. No long-term follow-up or postoperative data collection is planned, and the study aims to enroll 20 patients to inform future research.
Actively Recruiting
Researchers are evaluating the long-term clinical and instrumental response to Cardiac Contractility Modulation CCM therapy in adults with symptomatic heart failure caused by systolic left ventricular dysfunction despite adequate medical treatment. This observational cohort study, both retrospective and prospective, focuses on subjects already receiving CCM as part of their regular care. The study aims to assess clinical response, hospitalizations, quality of life, walking distance, and changes in heart biomarkers over 12 months. Participants carry the OPTIMIZER Smart Mini CCM device, a programmable implantable pulse generator connected to leads in the heart. The study groups are defined by their response to low-dose dobutamine stress echocardiography before implantation, with one group showing a reduction of 15% or more in left ventricular end-systolic volume LVESV and the other less than 15%. The low-dose dobutamine test involves incremental infusions of the drug to assess heart contractile reserve. During the 12-month follow-up, researchers will monitor changes in New York Heart Association NYHA class, hospitalizations, quality of life using the Minnesota Living with Heart Failure Questionnaire, walking test distance, and NT-proBNP biomarker levels. Additional assessments include echocardiographic measures and recording adverse events, cardiac device implants, or surgery. This comprehensive monitoring helps evaluate the clinical and functional effects of CCM therapy over time.